Lahore: Citi Pharma Ltd, a key player in the pharmaceutical sector, announced on February 13, 2026, that its Board of Directors convened to review the company's financial standing for the quarter ending December 31, 2025. In this latest disclosure, the company confirmed that no interim cash dividends, bonus shares, or right shares would be issued for the period.

The company's decision comes after a review meeting held at 13:30 in Lahore, where the Board resolved to maintain the status quo regarding shareholder entitlements. Specifically, no interim cash dividend was declared, maintaining a payout of Rs. NIL per share. Additionally, there were no bonus shares or right shares announced, with a proportion of NIL shares for each held, reflecting a NIL% increase.

According to information available from the Pakistan Stock Exchange (PSX), Citi Pharma Ltd has not introduced any new corporate actions or entitlements that could influence its share valuation. The board's resolution to refrain from issuing dividends or shares indicates a strategic pause in shareholder distributions.

Furthermore, the company outlined its financial results documentation, which includes comprehensive statements such as the Statement of Profit Loss, Statement of Financial Position, Statement of Changes in Equity, and Statement of Cash Flows. These documents are prepared to provide a detailed view of the company's financial health over the interim period and the cumulative financial year to date. The financial statements, available through PUCARS, will adhere to the regulatory requirements of being transmitted within 60 days of the second quarter's close.

Citi Pharma Ltd's decision to not distribute dividends or shares this quarter may reflect broader market conditions or internal strategies yet to be detailed publicly. The company's financial statements are expected to offer further insights into its earnings, equity changes, and cash flows, as well as any potential observations or qualifications by auditors.